Pages that link to "Q35120618"

The following pages link to Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. (Q35120618):

Displayed 35 items.

• Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS (Q26778450) ‎ (← links)
• Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV (Q26799712) ‎ (← links)
• Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir (Q34151623) ‎ (← links)
• A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma (Q34496927) ‎ (← links)
• Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects (Q34596882) ‎ (← links)
• Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. (Q34726183) ‎ (← links)
• The role of dolutegravir in the management of HIV infection (Q35121450) ‎ (← links)
• Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. (Q35607667) ‎ (← links)
• Potential benefit of dolutegravir once daily: efficacy and safety (Q36603416) ‎ (← links)
• Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation (Q36896981) ‎ (← links)
• Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir (Q37248656) ‎ (← links)
• Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. (Q37263531) ‎ (← links)
• Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine (Q37287684) ‎ (← links)
• Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management (Q37378110) ‎ (← links)
• Dolutegravir (Q37614157) ‎ (← links)
• Dolutegravir for the treatment of HIV. (Q37989555) ‎ (← links)
• Pharmacology of HIV integrase inhibitors (Q38025835) ‎ (← links)
• Dolutegravir: first global approval (Q38139885) ‎ (← links)
• Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection (Q38164678) ‎ (← links)
• Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. (Q38172029) ‎ (← links)
• Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection (Q38203844) ‎ (← links)
• Integrase Strand Transfer Inhibitors in HIV Therapy. (Q38240974) ‎ (← links)
• Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection (Q38541809) ‎ (← links)
• The pharmacological challenges of treating tuberculosis and HIV coinfections (Q39003762) ‎ (← links)
• Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use. (Q39007008) ‎ (← links)
• Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects (Q40121806) ‎ (← links)
• Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference (Q40282068) ‎ (← links)
• Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. (Q40478690) ‎ (← links)
• Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics (Q42249749) ‎ (← links)
• Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs (Q42265837) ‎ (← links)
• Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry (Q44401027) ‎ (← links)
• Dolutegravir: An Integrase Strand Transfer Inhibitor for the Treatment of Human Immunodeficiency Virus 1 in Adults. (Q55309394) ‎ (← links)
• Dolutegravir: a new option for HIV treatment (Q58290460) ‎ (← links)
• A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study (Q61810158) ‎ (← links)
• Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens? (Q64272820) ‎ (← links)